2024-09-01 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences is a biopharmaceutical company that develops and commercializes medicines for various diseases, including HIV/AIDS, hepatitis B and C, and cancer.

**1. Performance Comparison with S&P 500:**

GILD's cumulative return of 14.51% significantly lags behind the S&P 500 (VOO) with a cumulative return of 89.66%. The difference in performance stands at -75.15%, indicating a substantial underperformance. This relative underperformance falls at the 15.83 percentile within the historical data range.

**2. Recent Price Movement:**

* **Closing Price:** $79.0
* **5-day Moving Average:** $78.19
* **20-day Moving Average:** $75.47
* **60-day Moving Average:** $71.78

The price is currently above all three moving averages, suggesting a short-term bullish sentiment.

**3. Technical Indicators:**

* **RSI:** 87.42 - This high RSI reading indicates the stock is currently in overbought territory, suggesting a potential pullback in the near term.
* **PPO:** 0.4 - A positive PPO reading indicates a bullish signal, suggesting upward momentum.
* **Delta_Previous_Relative_Divergence:** -5.9 - This negative value indicates a slight decrease in the rate of price divergence, suggesting a potential slowdown in momentum. 
* **Expected Return:** 21.27% - This figure represents the maximum potential return based on current investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report shows an EPS of 1.29 and revenue of 6.95B$. While this is an improvement from the previous quarter, it is still important to consider the overall trend and the company's future prospects. 

**5. Overall Analysis:**

GILD is currently in overbought territory, with a high RSI reading and a positive PPO value suggesting bullish momentum. However, the negative Delta_Previous_Relative_Divergence and the significant underperformance compared to the S&P 500 raises some concerns. While recent earnings have shown improvement, further analysis is needed to assess the company's long-term growth potential and the impact of potential market volatility.

**6. Recommendations:**

Given the current state of the market, it is recommended to monitor GILD closely and consider the risks and potential rewards before making any investment decisions. Investors should consider the company's long-term prospects, future product pipeline, and potential competitive threats before making a decision. 
